Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The limitations of imaging response criteria.

Mehta VA, Sampson JH.

Lancet Oncol. 2012 Nov;13(11):1064-5. doi: 10.1016/S1470-2045(12)70458-8. No abstract available.

PMID:
23116995
2.

Targeting brain metastases in patients with melanoma.

Papadatos-Pastos D, Soultati A, Harries M.

Biomed Res Int. 2013;2013:186563. doi: 10.1155/2013/186563. Epub 2013 Dec 23. Review.

3.

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV.

Cancer. 2014 Feb 15;120(4):530-6. doi: 10.1002/cncr.28445. Epub 2013 Nov 5.

4.

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr, Lebowitz PF, Kefford RF, Long GV.

Eur J Cancer. 2013 Jan;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 14.

PMID:
22981500
5.

Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.

Lilly E, Burke M, Kluger H, Choi J.

JAMA Dermatol. 2015 Jan;151(1):102-3. doi: 10.1001/jamadermatol.2014.2455. No abstract available.

PMID:
25250477
6.

Rapid evolution of combination therapy in melanoma.

Curti BD.

N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158. No abstract available.

PMID:
25390744
7.

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.

J Clin Oncol. 2013 May 1;31(13):e220-2. doi: 10.1200/JCO.2012.44.4265. Epub 2013 Mar 25. No abstract available.

8.

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, Pöttgen C, Stuschke M, Schadendorf D, Zimmer L.

J Clin Oncol. 2013 Oct 20;31(30):3844-5. doi: 10.1200/JCO.2013.50.8473. Epub 2013 Sep 23. No abstract available.

9.

Melanoma combination therapies ward off tumor resistance.

Garber K.

Nat Biotechnol. 2013 Aug;31(8):666-8. doi: 10.1038/nbt0813-666b. No abstract available.

PMID:
23929325
10.

MAP-kinase pathway up or down? Just look at the skin of your patients!

Robert C, Thomas M, Mateus C.

Melanoma Res. 2014 Oct;24(5):421-3. doi: 10.1097/CMR.0000000000000114. No abstract available.

PMID:
25185691
11.

Discussion.

[No authors listed]

J Am Coll Surg. 2015 Apr;220(4):593-5. doi: 10.1016/j.jamcollsurg.2015.01.025. No abstract available.

PMID:
25797744
12.

Reply to N. Rompoti et al.

Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.

J Clin Oncol. 2013 Oct 20;31(30):3845-6. doi: 10.1200/JCO.2013.51.8936. Epub 2013 Sep 23. No abstract available.

13.

Treatment of BRAF inhibitor-induced hyperkeratosis.

Battley JE, Lenihan E, Redmond HP, Murphy M, Power DG.

Acta Oncol. 2013 May;52(4):874-7. doi: 10.3109/0284186X.2012.716165. Epub 2012 Sep 24. No abstract available.

PMID:
22998476
14.

Extending the reach of BRAF-targeted cancer therapy.

Gibney GT, Sondak VK.

Lancet. 2012 May 19;379(9829):1858-9. doi: 10.1016/S0140-6736(12)60610-2. No abstract available.

PMID:
22608322
15.

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW.

J Natl Cancer Inst. 2014 Dec 3;107(1):378. doi: 10.1093/jnci/dju378. Print 2015 Jan. No abstract available.

16.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. No abstract available.

17.

Effect of vemurafenib on a V600R melanoma brain metastasis.

van den Brom RR, de Vries EG, Schröder CP, Hospers GA.

Eur J Cancer. 2013 May;49(7):1795-6. doi: 10.1016/j.ejca.2013.02.009. Epub 2013 Mar 6. No abstract available.

PMID:
23473613
18.

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x. Epub 2012 Oct 5.

PMID:
22804352
19.

BRAF inhibitor activity in V600R metastatic melanoma--response.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV.

Eur J Cancer. 2013 May;49(7):1797-8. doi: 10.1016/j.ejca.2013.02.010. Epub 2013 Mar 13. No abstract available.

PMID:
23490649
20.

Dabrafenib in the treatment of advanced melanoma.

Medina T, Amaria MN, Jimeno A.

Drugs Today (Barc). 2013 Jun;49(6):377-85. doi: 10.1358/dot.2013.49.6.1968669. Review.

PMID:
23807941
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk